Pharmacokinetics and bioequivalence of sunitinib and Sutent® in Chinese healthy subjects: an open-label, randomized, crossover study

Purpose: The purpose of this study was to examine the pharmacokinetics (PK), bioequivalence and safety of generic sunitinib and its original product Sutent® in healthy Chinese subjects through a phase-I clinical trial.Methods: The study selected two groups of 24 healthy Chinese subjects in a 1:1 rat...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yanli Wang, Qiaohuan Deng, Zhenyue Gao, Guangwen Liu, Zhengjie Su, Yicheng Zhao, Lixiu Zhang, Haimiao Yang
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2023-11-01
Col·lecció:	Frontiers in Pharmacology
Matèries:	bioequivalence pharmacokinetics renal cell carcinoma sunitinib safety
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1294688/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!